News

Special Sections

Ra Medical Systems' $50 Million IPO Expected This Week

Ra Medical Systems' $50 Million IPO Expected This Week

Equities Research | Equities.com |

Excimer laser system to treat vascular and dermatological diseases (Image: Ra Medical Systems).


uBiome, Owner of Largest Human Microbiome Database, Raises $83 Million Series C Round

Equities Research | Equities.com |

Moving into drug discovery and development. Also adds ex Novartis CEO Joseph Jimenez to board (Image: uBiome).


Molecular Templates Signs Cancer Therapy Development Deal with Takeda Worth up to $663 Million

Equities Research | Equities.com |

Targeting CD38, a key biomarker in multiple myeloma and other cancers (Image: Molecular Templates).


Galera Therapeutics Secures $150 Million Series C for Oral Mucositis in Cancer Patients

Equities Research | Equities.com |

Equity + royalty financing for Phase 3 trial of lead product candidate in Q4 2018 (Image: Galera Therapeutics).


Braeburn Shows Positive Top-Line Phase 3 Data in Chronic Low Back Pain

Equities Research | Equities.com |

Weekly and monthly buprenorphine for patients previously on long-term daily opioid therapy (Image: Braeburn)


Y-mAbs Therapeutics' $80 Million IPO Expected This Week for Pediatric Cancer

Equities Research | Equities.com |

Two Phase 2 Breakthrough Therapy candidates licensed from Memorial Sloan Kettering (Image: Y-mAbs Therapeutics).


Boehringer Ingelheim Acquires ViraTherapeutics and its Oncolytic Virus Program for $245 Million

Equities Research | Equities.com |

Third major acquisition of an oncolytic virus company by Big Pharma this year (Image: UCLA Jonsson Comprehensive Cancer Center).


Principia Biopharma's $75 Million IPO Expected This Week for Small Molecule Drug Discovery

Equities Research | Equities.com |

Novel drug discovery platform with programs in immunology, central nervous system disorders and oncology (Image: Principia Biopharma).


Merck KGaA and Pfizer Show that Phase 3 Combination Therapy Delays Progression of Kidney Cancer

Equities Research | Equities.com |

Bavencio (avelumab) + Inlyta (axitinib) show statistically significant improvement in progression-free survival vs Sutent (sunitinib) (Image: prIME Oncology).


Kodiak Sciences Files $100 Million IPO for Chronic Retinal Diseases

Equities Research | Equities.com |

Lead candidate targeting wet age-related macular degeneration and diabetic retinopathy.


Emerging Growth

Singlepoint Inc

SinglePoint Inc is a mobile technology company engaged in mobile payments, mobile giving, and mobile bidding. It operates mobile commerce and communications platform to accept mobile credit card payments.

Events

Guild's Quarterly Forecast

Join the whole Guild team on Wednesday, September 26 at 10 AM PDT for Guild’s Quarterly Forecast, our regular conference call and webinar on the most important trends affecting your…

Learn more